BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38447209)

  • 21. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
    Llovet JM; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
    Cardiovasc Intervent Radiol; 2022 Apr; 45(4):405-412. PubMed ID: 35119481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
    Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
    Teng Y; Ding X; Li W; Sun W; Chen J
    Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial.
    Yoshimi F; Nagao T; Inoue S; Kawano N; Muto T; Gunji T; Ohnishi S; Imawari M
    Hepatology; 1992 Sep; 16(3):702-6. PubMed ID: 1324216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
    Lang H; Ricke J; Schlaak J
    Dtsch Med Wochenschr; 2013 Sep; 138(36):1780-4. PubMed ID: 23943578
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful hepatocellular carcinoma downstaging with transarterial chemoembolization followed by stereotactic radiotherapy.
    Jacob R; Saddekni S; Dover L; DuBay DA
    Liver Transpl; 2016 Apr; 22(4):547-51. PubMed ID: 26785388
    [No Abstract]   [Full Text] [Related]  

  • 29. Spinal cord injury subsequent to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Kim JH; Yeon JE; Jong YK; Seo WK; Cha IH; Seo TS; Park JJ; Kim JS; Bak YT; Byun KS
    Dig Liver Dis; 2010 Jan; 42(1):67-70. PubMed ID: 19546038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma.
    Habibollahi P; Shamchi SP; Tondon R; Ecker BL; Gade TP; Hunt S; Soulen MC; Furth EE; Levine MH; Nadolski G
    J Vasc Interv Radiol; 2018 Feb; 29(2):237-243. PubMed ID: 29221923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience of the treatment following downstaging of larger hepatocellular carcinomas by transcathetheter hepatic arterial chemoembolization in 58 patients].
    Jin X; Shi XJ; Wang MQ; Wei LX; Ye HY; Liang YR; Luo Y; Dong JH
    Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(14):950-5. PubMed ID: 21609544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Major achievements in hepatocellular carcinoma.
    Bruix J; Llovet JM
    Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract]   [Full Text] [Related]  

  • 33. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
    Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
    Qu WF; Ding ZB; Qu XD; Tang Z; Zhu GQ; Fu XT; Zhang ZH; Zhang X; Huang A; Tang M; Tian MX; Jiang XF; Huang R; Tao CY; Fang Y; Gao J; Wu XL; Zhou J; Fan J; Liu WR; Shi YH
    BJS Open; 2022 Sep; 6(5):. PubMed ID: 36125345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver tumors and loco-regional therapy.
    Vogel W
    Wien Med Wochenschr; 2013 Mar; 163(5-6):107-8. PubMed ID: 23456251
    [No Abstract]   [Full Text] [Related]  

  • 37. [A case of advanced hepatocellular carcinoma wherein readministration was made possible due to successful transcatheter arterial embolization for intratumoral hemorrhage during Lenvatinib administration].
    Hara H; Nakano Y; Arai K; Kaneko Y; Sakaki K; Fukami Y; Ikemiyagi H; Yoshino K; Sakita S
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(5):476-485. PubMed ID: 35545547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Chan SL; Johnson P
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):111-4. PubMed ID: 22524569
    [No Abstract]   [Full Text] [Related]  

  • 39. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
    Li X; Xu J; Gu X; Chen L; Wu Q; Li H; Bai H; Yang J; Qian J
    Front Immunol; 2021; 12():740790. PubMed ID: 34733279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.